Literature DB >> 7807279

Reactivity of chagasic sera with crude and highly purified glycosphingolipid fractions from Trypanosoma cruzi epimastigotes.

M H Boas1, M C da Silva, T G de Oliveira, L R Travassos, E B Bergter.   

Abstract

The reactivities of sera from patients with Chagas disease or from T. cruzi-immunized rabbits with two different lipid preparations of T. cruzi were assessed using epimastigote antigens. Serum reactivities were determined using a quantitative enzyme-linked immunosorbent assay (ELISA). Antigen 1 represents the lower phase obtained from crude lipid extract after Folch partition (LCL). Antigen 2 is a highly purified glycosphingolipid fraction (GSL). The LCL antigen discriminated quite well the reactivities of Chagasic patients' sera and sera from healthy individuals, as well as between the serum from a T. cruzi-immunized rabbit (TIRS) and normal rabbit serum (NRS). A strong reactivity with GSL was obtained with TIRS. Reactivity with GSL was also obtained with human Chagasic sera. Compared to a group of normal individuals, the reactions of antibodies directed against lipid antigens were considerably increased in sera of patients with Chagas disease. Chagasic sera did not differentiate between glycolipids with terminal beta-glucosyl or beta-galactosyl non-reducing units. They discriminated, however, glucosylceramides with differences in the ceramide structure. To determine the specificity of Chagasic sera, antibodies isolated on LCL-immunosorbent (LCL-Ch Abs) as well as on laminin-immunosorbent (Lam-Ch Abs) were tested against laminin and LCL antigens. We found that Lam-Ch Abs reacted with murine laminin, whereas the reaction was negative with LCL. In contrast, the LCL-Ch Abs reacted either with LCL antigens or with laminin. The reactivity with laminin was strong in comparison with LCL.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7807279     DOI: 10.1002/jcla.1860080503

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  3 in total

Review 1.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

2.  Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth.

Authors:  M L Rodrigues; L R Travassos; K R Miranda; A J Franzen; S Rozental; W de Souza; C S Alviano; E Barreto-Bergter
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Antiviral activity of glucosylceramides isolated from Fusarium oxysporum against Tobacco mosaic virus infection.

Authors:  Mariana C Bernardino; Michel Leon C O Couto; Maite F S Vaslin; Eliana Barreto-Bergter
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.